GlassScriptPhysician profile
Vinetta M Mccann
NPI 1134193113
$15,550.46
in general payments reported to CMS, 2019-2025
18 companies · $7,575 in 2025
The $7,575 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.36 · 2023: $539 · 2024: $7,394 · 2025: $7,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,815 · Travel and Lodging: $3,517 · Food and Beverage: $3,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,815.00 |
| Travel and Lodging | $3,516.84 |
| Food and Beverage | $3,176.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13,270.81 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,150.94 | 2023-2025 | |
| Pfizer INC. | $236.41 | 2024-2025 | |
| Lilly USA, LLC | $168.27 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Biotech, INC. | $122.44 | 2024-2025 | Tremfya |
| Ardelyx, INC. | $120.88 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $89.06 | 2023 | |
| Daiichi Sankyo INC. | $85.06 | 2022-2024 | Injectafer |
| Gilead Sciences, INC. | $74.26 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $45.39 | 2025 | Zenpep, Vowst |
| Amgen INC. | $40.14 | 2022-2023 | Otezla, Repatha |
| Qol Medical, LLC | $34.87 | 2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $28.15 | 2023-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $22.67 | 2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $16.75 | 2023 | Dificid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.03 | 2022 | |
| Eisai INC. | $15.25 | 2024 | |
| Alnylam Pharmaceuticals INC. | $13.08 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinetta Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.